THE EFFECTS OF ENALAPRIL AND IRBESARTAN IN EXPERIMENTAL DIABETIC NEPHROPATHY
BIOTECHNOLOGY AND BIOTECHNOLOGICAL EQUIPMENT, sa.3, ss.366-371, 2007 (Scopus)
- Yayın Türü: Makale / Tam Makale
- Basım Tarihi: 2007
- Dergi Adı: BIOTECHNOLOGY AND BIOTECHNOLOGICAL EQUIPMENT
- Derginin Tarandığı İndeksler: Scopus
- Sayfa Sayıları: ss.366-371
- Kütahya Sağlık Bilimleri Üniversitesi Adresli: Hayır
Özet
In our study we investigated the effects of angiotensin converting enzyme inhibitor and Angiotensin T1
receptor blocker at lowdoses which do not affect blood pressure and renal hemodynamia on the experimental diabetic nephropathy.
Diabetes mellitus was induced by 50 mg/kg streptozotocin on Sprague-Dawley rats. Except for the patient control group, 2.5
mg/kg Enalapril (an angiotensin converting enzyme inhibitor) and 5 mg/kg Irbesartan (an Angiotensin T1
receptor blocker) were
given everyday via drinking water during six weeks period. After 24-hour urine collection, blood was withdrawn by cardiac
puncture, and rats were sacrifi ced. Renal functions, histopathologic and electron microscopic alterations in renal tissues, and
relative percent deposition of type IV Collagen were investigated. Diabetic nephropathy was determined with the increase of
plasma glucose, HbAэC (P<0.000), urea, creatinin (P<0.005) and urinary protein, albumin, glucose (P<0.000) in patient control
and Enalapril and Irbesartan treatment groups when compared to the healthy control group.
Mesangiocellular proliferation, tubular basement membrane thickness, percentage of glomerular collagen accumulation reduced
in treatment groups and glucose in urine in Enalapril group declined.
Our fi ndings suggest that renal protective effects of Enalapril and Irbesartan in the development of diabetic nephropathy were
comparable.